AR116526A1 - Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g - Google Patents

Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g

Info

Publication number
AR116526A1
AR116526A1 ARP190102737A ARP190102737A AR116526A1 AR 116526 A1 AR116526 A1 AR 116526A1 AR P190102737 A ARP190102737 A AR P190102737A AR P190102737 A ARP190102737 A AR P190102737A AR 116526 A1 AR116526 A1 AR 116526A1
Authority
AR
Argentina
Prior art keywords
hla
mediated
suppression
seq
inhibits
Prior art date
Application number
ARP190102737A
Other languages
English (en)
Spanish (es)
Original Assignee
Tizona Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68296637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR116526(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tizona Therapeutics filed Critical Tizona Therapeutics
Publication of AR116526A1 publication Critical patent/AR116526A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
ARP190102737A 2018-09-27 2019-09-26 Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g AR116526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862737666P 2018-09-27 2018-09-27

Publications (1)

Publication Number Publication Date
AR116526A1 true AR116526A1 (es) 2021-05-19

Family

ID=68296637

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP190102737A AR116526A1 (es) 2018-09-27 2019-09-26 Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g
ARP230102177A AR130233A2 (es) 2018-09-27 2023-08-16 Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP230102177A AR130233A2 (es) 2018-09-27 2023-08-16 Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g

Country Status (27)

Country Link
US (4) US11208487B2 (https=)
EP (1) EP3856780A1 (https=)
JP (2) JP7588068B2 (https=)
KR (1) KR102867868B1 (https=)
CN (2) CN113166243B (https=)
AR (2) AR116526A1 (https=)
AU (1) AU2019346598B2 (https=)
BR (1) BR112021005868A2 (https=)
CA (1) CA3114407A1 (https=)
CL (2) CL2021000761A1 (https=)
CO (1) CO2021004719A2 (https=)
CR (1) CR20210197A (https=)
DO (1) DOP2021000049A (https=)
EA (1) EA202190609A1 (https=)
EC (1) ECSP21026339A (https=)
IL (1) IL281778A (https=)
MX (1) MX2021003555A (https=)
MY (1) MY204959A (https=)
NZ (1) NZ774376A (https=)
PE (1) PE20211767A1 (https=)
PH (1) PH12021550690A1 (https=)
SG (1) SG11202103104RA (https=)
TW (2) TW202438522A (https=)
UA (1) UA129052C2 (https=)
UY (1) UY38391A (https=)
WO (1) WO2020069133A1 (https=)
ZA (2) ZA202102034B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428604A (zh) 2018-07-09 2024-07-16 美商戊瑞治療有限公司 結合至ilt4的抗體
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
IL298867A (en) * 2020-06-11 2023-02-01 Tizona Therapeutics Bispecific immune cell engagers with binding specificity for hla-g and another antigen
WO2022159620A1 (en) * 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
US12012454B2 (en) * 2021-03-24 2024-06-18 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN115925930B (zh) * 2021-11-04 2025-10-31 台州恩泽医疗中心(集团) 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途
WO2023182866A1 (ko) * 2022-03-25 2023-09-28 에이치케이이노엔 주식회사 Hla-g 특이적 항체 및 이의 용도
CN115819583B (zh) * 2022-03-31 2026-03-03 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途
US20250223363A1 (en) * 2022-04-08 2025-07-10 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47
CN119768507A (zh) * 2022-06-24 2025-04-04 怡诺安有限公司 表达免疫检查点调节剂的免疫细胞及其用途
CN117448412A (zh) * 2022-07-26 2024-01-26 中山大学孙逸仙纪念医院 CD158d分子、其中和抗体，及应用
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN119569891B (zh) * 2023-09-06 2025-09-05 上海恩凯细胞技术有限公司 用于癌症治疗的靶向非经典hla分子的嵌合抗原受体的应用
GB202319122D0 (en) * 2023-12-14 2024-01-31 Kbio Holdings Ltd Antibody
WO2025165879A1 (en) 2024-01-29 2025-08-07 Tizona Therapeutics, Inc. Methods of using anti-hla-g antibodies
WO2025245256A1 (en) 2024-05-22 2025-11-27 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
EP0819171A1 (en) 1995-04-07 1998-01-21 The Regents Of The University Of California Antibodies for the detection of hla-g
ES2224603T3 (es) 1998-02-20 2005-03-01 Commissariat A L'energie Atomique Procedimiento de seleccion de tumores que expresan hla-g sensibles a un tratamiento anticanceroso y sus aplicaciones.
CA2425186A1 (en) 2000-09-15 2002-03-21 University Of Kansas Medical Center Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
ES2430857T3 (es) 2000-12-18 2013-11-22 Dyax Corp. Bibliotecas focalizadas de paquetes genéticos
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
WO2005042693A2 (ja) 2003-11-04 2005-05-12 The Animal Engineering Research Institute Ｈｌａ−ｅキメラ分子
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CN1312182C (zh) 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2445935B1 (en) 2009-06-25 2015-07-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof
CN101967191A (zh) 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
US20190119385A1 (en) 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
PT3294764T (pt) 2015-05-15 2021-02-15 Hope City Composições de recetores de antigénios quiméricos
NZ748929A (en) * 2016-06-03 2025-11-28 Invectys Anti hla-g specific antibodies
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AU2019328677A1 (en) 2018-08-31 2021-04-01 Invectys SA Chimeric antigen receptors against multiple HLA-G isoforms

Also Published As

Publication number Publication date
CR20210197A (es) 2021-06-03
CN115057932B (zh) 2026-04-21
DOP2021000049A (es) 2021-10-31
US11208487B2 (en) 2021-12-28
JP7588068B2 (ja) 2024-11-21
MY204959A (en) 2024-09-25
JP2024177227A (ja) 2024-12-19
US20210340259A1 (en) 2021-11-04
MX2021003555A (es) 2021-05-27
US20200102390A1 (en) 2020-04-02
SG11202103104RA (en) 2021-04-29
EA202190609A1 (ru) 2021-08-17
ZA202102034B (en) 2022-09-28
US20250353913A1 (en) 2025-11-20
UA129052C2 (uk) 2025-01-01
EP3856780A1 (en) 2021-08-04
US20220135689A1 (en) 2022-05-05
NZ774376A (en) 2025-11-28
PH12021550690A1 (en) 2022-02-28
CA3114407A1 (en) 2020-04-02
CN113166243B (zh) 2023-03-24
UY38391A (es) 2020-04-30
ZA202201874B (en) 2025-05-28
KR20210098956A (ko) 2021-08-11
PE20211767A1 (es) 2021-09-07
CL2021000761A1 (es) 2021-09-10
TW202438522A (zh) 2024-10-01
CL2023002048A1 (es) 2023-12-22
AU2019346598A1 (en) 2021-04-29
CN115057932A (zh) 2022-09-16
IL281778A (en) 2021-05-31
KR102867868B1 (ko) 2025-10-13
JP2022502052A (ja) 2022-01-11
TWI828767B (zh) 2024-01-11
AU2019346598B2 (en) 2026-02-26
ECSP21026339A (es) 2021-07-30
BR112021005868A2 (pt) 2021-10-19
WO2020069133A1 (en) 2020-04-02
CN113166243A (zh) 2021-07-23
TW202035456A (zh) 2020-10-01
AR130233A2 (es) 2024-11-20
CO2021004719A2 (es) 2021-05-31
US12264199B2 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
AR116526A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g
Surowka et al. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
JP7662516B2 (ja) Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用
EP3694882B1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
AR111203A1 (es) Inmunoconjugados
JP2018524326A5 (https=)
AR110101A1 (es) Miembros de unión (2)
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
RU2016114504A (ru) Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
PE20181089A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
GB2518221A (en) Tetravalent antigen-binding protein molecule
AR109533A2 (es) Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios
AU2018280683A1 (en) Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
JP2016512216A5 (https=)
US11945863B2 (en) CD33-, CD16- and CD123-specific single chain triplebody
PE20200010A1 (es) Anticuerpos que se unen a steap-1
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
PE20251170A1 (es) Anticuerpos cd200r disenados por ingenieria y usos de estos
BR112019013955A2 (pt) Composições e métodos relacionados a construtos de fc manipulados
CN115996952A (zh) 对hla-g和另一种抗原具有结合特异性的双特异性免疫细胞接合子
PH12022500029A1 (en) Anti-pd-1 antibodies and fusion proteins
JP2023552829A (ja) 免疫細胞機能を調節するための変異インターロイキン－１０ポリペプチドの抗原結合分子との融合物
PE20240224A1 (es) Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8
BR112021000391A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4